Furthermore, the tetracycline-controllable shRNA can control the expression level of HOXD-AS1 in a dose-dependent manner and inhibit the development of bladder cancer cells, which may open up a novel way for treating bladder cancer. This evidence concerns the gene HAGLR and urinary bladder carcinoma.